Merrimack Pharmaceuticals and Sanofi-Aventis Sign Licensing Agreement for Potential Cancer Drug

Download IconDownload Print IconPrint

Merrimack Pharmaceuticals and Sanofi-Aventis Sign Licensing Agreement for Potential Cancer Drug

Client News

Related Solutions

We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
On October 1, Merrimack Pharmaceuticals and sanofi-aventis announced the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121 -- Merrimack's first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. The ErbB3 receptor is a novel target known to be a key mediator of signaling in the ErbB pathway (also known as the EGFR or HER pathway) – a signaling network that impacts a broad array of cancers.

Under the agreement, sanofi-aventis will pay Merrimack $60 million upfront and will be responsible for all development costs. Merrimack is eligible for an additional $470 million in milestone payments as well as tiered double-digit royalties on sales of MM-121. Merrimack will execute the development of MM-121 (which is currently in Phase 1 clinical testing), for each indication and sanofi-aventis will be responsible for development thereafter. Merrimack also retains the right to co-promote the therapy in the United States.

WilmerHale represented Merrimack in this matter. David Redlick led the WilmerHale team, which also included Steven Barrett and Soojin Chung.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel